Difference between revisions of "HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2 (Q11017)"

@@ Property / title @@
+HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English)
+Normal rank
@@ Property / Publication Date @@
+Timestamp +2020-01-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 year
Before 0
After 0
-Timestamp
++2020-01-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+year
 Before
 After
@@ Property / Publication Date: 2020 / rank @@
+Normal rank
@@ Property / First Author string @@
+HFSA/ACC/AHA
@@ Property / First Author string: HFSA/ACC/AHA / rank @@
+Normal rank
@@ Property / publication URL @@
+https://www.hfsa.org/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician/
+Normal rank
@@ links / sliswiki / name / links / sliswiki / name @@
+HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2

Latest revision as of 14:40, 22 June 2020

Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.

Language	Label	Description	Also known as
English	HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2	Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.